AstraZeneca's Tagriso trial shows 'meaningful improvement', Lynparza recommended for EU marketing
By Iain Gilbert
Date: Monday 21 Sep 2020
(Sharecast News) - Pharmaceutical giant AstraZeneca issued updates on the status of several drug candidates early on Monday.
AstraZeneca said a Phase III trial on Tagrisso had demonstrated a "clinically meaningful improvement" in central nervous system disease-free survival in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer, after complete tumour resection.
The FTSE 250-listed firm said analysis of the trial showed that only 11% of patients had recurrence events or deaths when using the drug compared to the 46% seen by those using the placebo. Among patients whose cancer recurred, 38% of those treated with Tagrisso had a metastatic recurrence compared to 61% of patients on placebo.
Elsewhere, AstraZeneca said Lynparza, its poly ADP ribose polymerase inhibitor, had been recommended for marketing authorisation by the European for patients with both metastatic castration-resistant prostate cancer and as a first-line treatment for patients with homologous recombination deficient-positive advanced ovarian cancer.
As of 0830 BST, AstraZeneca shares were down 0.30% at 8,720.07p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN